Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2021

Feb 14, 2022

SELL
$6.35 - $47.04 $1.21 Million - $8.94 Million
-190,000 Closed
0 $0
Q3 2021

Nov 15, 2021

BUY
$20.88 - $56.08 $3.97 Million - $10.7 Million
190,000 New
190,000 $8.03 Million

Others Institutions Holding ADGI

About Adagio Therapeutics, Inc.


  • Ticker ADGI
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 108,831,000
  • Market Cap $505M
  • Description
  • Adagio Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company's lead product candidate is the ADG20 (adintrevimab), a neutralizing antibody that is in Phase 3 clinical trials for the treatmen...
More about ADGI
Track This Portfolio

Track Antipodean Advisors LLC Portfolio

Follow Antipodean Advisors LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Antipodean Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Antipodean Advisors LLC with notifications on news.